(Q34205687)

31 July 2017

title

Response to ustekinumab in a patient with both severe psoriasis and hypertrophic cutaneous lupus (English)

1 reference

31 July 2017

1 reference

D Winchester

1

1 reference

31 July 2017

K Callis Duffin

series ordinal

2

1 reference

31 July 2017

C Hansen

series ordinal

3

1 reference

31 July 2017

language of work or name

1 reference

21 March 2012

1 reference

31 July 2017

1 reference

31 July 2017

volume

21

1 reference

31 July 2017

issue

9

1 reference

31 July 2017

page(s)

1007-1010

1 reference

https://api.crossref.org/works/10.1177%2F0961203312441982

31 July 2017

1 reference

Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203312441982

21 January 2018

Anti-TNF-induced lupus

1 reference

https://api.crossref.org/works/10.1177%2F0961203312441982

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203312441982

The relation of interleukin 17 (IL-17) and IL-23 to Th1/Th2 cytokines and disease activity in systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203312441982

IL-17 in cutaneous lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203312441982

T-helper 17 cells in psoriatic plaques and additional genetic links between IL-23 and psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203312441982

21 January 2018

Identifiers

DOI

10.1177/0961203312441982

1 reference

31 July 2017

1 reference